Brief: Innate Pharma To Present IPH6501 Preclinical Data At The EHA 2023 Congress

Innate Pharma SA

15/05/2023 06:09

May 15 (Reuters) - Innate Pharma SA  IPH.PA :
    * TO PRESENT IPH6501 PRECLINICAL DATA AT THE EHA 2023
CONGRESS
    * IPH6501, A FIRST-IN-CLASS TETRA-SPECIFIC ANTIBODY-BASED
NATURAL
KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF
B-CELL NON-HODGKIN'S LYMPHOMAS, SELECTED FOR ORAL PRESENTATION

Source text for Eikon:  ID:nBwJwJhxa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))